PTC Therapeutics Inc Q1 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : The first one is for your DMD portfolio, could you talk specifically about what's been the biggest driver in new patient starts? And is this also related to the specific geographies with more patient add? And then just kind of on top of that bigger picture question here, given you have a few registrational trials on deck. What's been the biggest learning factor in being able to expand your footprint globally? And how do you think you can leverage this should some of these candidates end up crossing the finish line soon.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Yes. That's helpful. And then maybe just one quick one on Huntington's disease. An oral drug obviously comes with benefits in terms of compliance and adherence. But thinking about the different therapeutics out there and recognizing the mechanisms are different. How are you thinking about an oral agent's ability to really target the right areas in the brain versus some other routes of administration that are being evaluated.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Great. Looking forward to catching up with you once the data readout.